Literature DB >> 1281421

Intracranial germ cell tumours: I. Experience with platinum based chemotherapy and implications for curative chemoradiotherapy.

D J Sebag-Montefiore1, E Douek, J E Kingston, P N Plowman.   

Abstract

The results of treatment with platinum based combination chemotherapy in ten patients with intracranial germ cell tumours (GCT) are presented. Two patients, treated for relapse within the central nervous system (CNS), attained partial responses of short duration. One patient with systemic relapse was successfully salvaged with chemotherapy. Seven patients received primary chemotherapy, six of whom received a 'CNS friendly' regimen consisting of vincristine, etoposide, carboplatin (VEJ) prior to craniospinal axis (CSA) irradiation. Three complete and three partial responses, and one patient with stable disease, were seen prior to irradiation. All seven patients are alive and remain disease-free at a median time of 12 months after treatment. Current treatment policy for germinomas attaining complete response to two courses of VEJ is a lowered CSA dose prescription, while non-germinomatous germ cell tumours (NGGCT) receive standard total dose CSA irradiation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1281421     DOI: 10.1016/s0936-6555(05)81122-7

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  3 in total

1.  Harvesting blood stem cells from cranial bone at craniotomy--a preliminary study.

Authors:  Tomomi Iwashita; Tsuyoshi Tada; Hua Zhan; Yuichiro Tanaka; Kazuhiro Hongo
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

2.  Treatment of intracranial nongerminomatous germ-cell tumor by high-dose chemotherapy and autologous stem-cell rescue.

Authors:  T Tada; T Takizawa; F Nakazato; S Kobayashi; K Koike; M Oguchi; E Ishii; Y Amano
Journal:  J Neurooncol       Date:  1999-08       Impact factor: 4.130

Review 3.  Chemotherapy for high-grade gliomas.

Authors:  E Galanis; J Buckner
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.